Altimmune (NASDAQ:ALT) Research Coverage Started at UBS Group

UBS Group began coverage on shares of Altimmune (NASDAQ:ALT) in a research note issued to investors on Tuesday, Marketbeat reports. The firm issued a buy rating and a $26.00 target price on the stock.

Other research analysts also recently issued reports about the company. Evercore ISI raised Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research note on Thursday, August 22nd. Finally, B. Riley reissued a “buy” rating and issued a $20.00 price objective on shares of Altimmune in a research note on Monday, August 12th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Altimmune presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Altimmune Stock Down 11.2 %

Shares of NASDAQ ALT opened at $8.46 on Tuesday. The business’s 50 day moving average price is $6.99 and its 200 day moving average price is $6.90. The firm has a market cap of $600.91 million, a P/E ratio of -5.45 and a beta of 0.09. Altimmune has a 52 week low of $2.34 and a 52 week high of $14.84.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 52.60% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter. During the same quarter in the prior year, the company posted ($0.39) EPS. As a group, research analysts expect that Altimmune will post -0.54 earnings per share for the current year.

Insider Activity at Altimmune

In other news, Director David Drutz sold 16,011 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the sale, the director now owns 41,958 shares of the company’s stock, valued at approximately $289,510.20. This trade represents a 27.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Bellevue Group AG boosted its stake in shares of Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after buying an additional 263,660 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Altimmune by 142.9% in the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after acquiring an additional 335,444 shares during the last quarter. Knoll Capital Management LLC raised its holdings in shares of Altimmune by 183.6% in the first quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock worth $5,774,000 after acquiring an additional 367,219 shares during the last quarter. Farallon Capital Management LLC lifted its position in Altimmune by 1,282.4% during the first quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock worth $4,785,000 after buying an additional 436,000 shares during the period. Finally, BBR Partners LLC lifted its position in Altimmune by 4.5% during the second quarter. BBR Partners LLC now owns 374,784 shares of the company’s stock worth $2,492,000 after buying an additional 16,271 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.